Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 33 (2), 329-332

A Randomized, Double-Blind, Placebo-Controlled Trial of Camicinal in Parkinson's Disease

Affiliations
Clinical Trial

A Randomized, Double-Blind, Placebo-Controlled Trial of Camicinal in Parkinson's Disease

Sarah L Marrinan et al. Mov Disord.

Abstract

Background: Delayed gastric emptying may impair l-dopa absorption, contributing to motor fluctuations. We evaluated the effect of camicinal (GSK962040), a gastroprokinetic, on the absorption of l-dopa and symptoms of PD.

Methods: Phase II, double-blind, placebo-controlled trial. Participants were randomized to receive camicinal 50 mg once-daily (n = 38) or placebo (n = 20) for 7 to 9 days.

Results: l-dopa exposure was similar with coadministration of camicinal compared to placebo. Median time to maximum l-dopa concentration was reduced, indicating more rapid absorption of l-dopa. Camicinal resulted in significant reduction in OFF time (-2.31 hours; 95% confidence interval: -3.71, -0.90), significant increase in ON time (+1.88 hours; 95% confidence interval: 0.28, 3.48) per day, and significant decrease in mean total MDS-UPDRS score (-12.5; 95% confidence interval: -19.67, -5.29). Camicinal treatment was generally well tolerated.

Conclusions: PD symptom improvement with camicinal occurred in parallel with more rapid absorption of l-dopa. This study provides evidence of an improvement of the motor response to l-dopa in people with PD treated with camicinal 50 mg once-daily compared with placebo, which will require further evaluation. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Trial registration: ClinicalTrials.gov NCT01602549.

Keywords: Clinical trials Randomized controlled (CONSORT agreement); Parkinson's disease/parkinsonism.

Figures

Figure 1
Figure 1
Correlation between change from baseline in OFF time and levodopa Tmax on day 8.

Comment in

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Cloud LJ, Greene JG. Gastrointestinal features of Parkinson's disease. Curr Neurol Neurosci Rep 2011;11:379‐384. - PubMed
    1. Heetun ZS, Quigley EM. Gastroparesis and Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2012;18:433‐440. - PubMed
    1. Doi H, Sakakibara R, Sato M, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. J Neurol Sci 2012;319:86‐88. - PubMed
    1. Muller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 2006;29:61‐67. - PubMed
    1. Djaldetti R, Koren M, Ziv I, Achiron A, Melamed E. Effect of cisapride on response fluctuations in Parkinson's disease. Mov Disord 1995;10:81‐84. - PubMed

Publication types

MeSH terms

Substances

Associated data

Feedback